Format

Send to

Choose Destination
See comment in PubMed Commons below
MAbs. 2009 Jul-Aug;1(4):326-31. Epub 2009 Jul 1.

Ofatumumab.

Author information

1
Harvard University, Department of Health Policy and Management, School of Public Health, Boston, MA 02115, USA. bozhang@hsph.harvard.edu

Abstract

Ofatumumab is an anti-CD20 IgG1kappa human monoclonal antibody that is being considered by the US Food and Drug Administration and the European Medicines Agency for marketing approval as a treatment for chronic lymphocytic leukemia. The mAb is also being studied as a treatment for lymphoma, rheumatoid arthritis and multiple sclerosis. The candidate targets the same antigen as rituximab, but ofatumumab binds a novel, membrane-proximal epitope, and dissociates from its target at a slower rate compared to rituximab. Ofatumumab might be approved in the US by August 2009.

PMID:
20068404
PMCID:
PMC2726602
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center